PTCT insider buying and SEC filings, explained
PTC Therapeutics, Inc. · CIK 1070081
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- PTC THERAPEUTICS INC
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$56.8M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 14, 2026 | Planned (10b5-1) | Michael Schmertzler (Director) sold 2,500 shares indirectly at about $59.61 ($149K), marked as a 10b5-1 plan trade. Indirect holdings down <1% to 1,291,594 shares. | SEC filing Filed Oct 16, 2026, 5:20 PM ET |
| Oct 9, 2026 | Planned (10b5-1) | Mark Elliott Boulding (Exec. VP and CLO) sold 192 shares at about $64.26 ($12K), marked as a 10b5-1 plan trade. Holdings down <1% to 105,272 shares. | SEC filing Filed Oct 13, 2026, 5:20 PM ET |
| Oct 7, 2026 | Planned (10b5-1) | Michael Schmertzler (Director) sold 2,500 shares indirectly at about $63.39 ($158K), marked as a 10b5-1 plan trade. Indirect holdings down <1% to 1,294,094 shares. | SEC filing Filed Oct 9, 2026, 5:20 PM ET |
| Oct 5–6, 2026 | Planned (10b5-1) | Mark Elliott Boulding (Exec. VP and CLO) sold 2,073 shares between Oct 5 and Oct 6 at about $64.06 ($133K), marked as a 10b5-1 plan trade. Holdings down 2% to 105,272 shares. | SEC filing Filed Oct 7, 2026, 5:20 PM ET |
| Sep 30, 2026 | Planned (10b5-1) | Glenn Md Phd Steele Jr. (Director) sold 12,000 shares at $65.16 ($782K), marked as a 10b5-1 plan trade. Holdings down 35% to 22,500 shares. | SEC filing Filed Oct 2, 2026, 5:20 PM ET |
| Sep 16–17, 2026 | Planned (10b5-1) | Michael Schmertzler (Director) sold 20,000 shares indirectly between Sep 16 and Sep 17 at about $67.49 ($1.3M), marked as a 10b5-1 plan trade. Indirect holdings down 2% to 1,296,594 shares. | SEC filing Filed Sep 18, 2026 |
| Sep 9–10, 2026 | Planned (10b5-1) | Michael Schmertzler (Director) sold 20,000 shares indirectly between Sep 9 and Sep 10 at about $67.59 ($1.4M), marked as a 10b5-1 plan trade. Indirect holdings down 1% to 1,316,594 shares. | SEC filing Filed Sep 11, 2026 |
| Aug 26–27, 2026 | Planned (10b5-1) | Michael Schmertzler (Director) sold 25,000 shares indirectly between Aug 26 and Aug 27 at about $72.26 ($1.8M), marked as a 10b5-1 plan trade. Indirect holdings down 2% to 1,336,594 shares. | SEC filing Filed Aug 28, 2026 |
| Aug 19–20, 2026 | Planned (10b5-1) | Michael Schmertzler (Director) sold 25,000 shares indirectly between Aug 19 and Aug 20 at about $72.22 ($1.8M), marked as a 10b5-1 plan trade. Indirect holdings down 2% to 1,361,594 shares. | SEC filing Filed Aug 21, 2026 |
| Aug 17, 2026 | Planned (10b5-1) | Mark Elliott Boulding (Exec. VP and CLO) sold 2,813 shares at about $72.57 ($204K), marked as a 10b5-1 plan trade. Holdings down 3% to 105,272 shares. | SEC filing Filed Aug 19, 2026 |
| Aug 4, 2026 | Planned (10b5-1) | Matthew B. Klein (CEO and Director) sold 10,292 shares at $68.57 ($706K), marked as a 10b5-1 plan trade. Holdings down 3% to 383,868 shares. | SEC filing Filed Aug 6, 2026 |
| Jul 14, 2026 | Planned (10b5-1) | Pierre Gravier (CFO) sold 3,494 shares at $80.35 ($281K), marked as a 10b5-1 plan trade. Holdings down 4% to 83,986 shares. | SEC filing Filed Jul 16, 2026 |
| Jul 9, 2026 | Planned (10b5-1) | Mary L. Smith (Director) sold 15,834 shares at $90.00 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 42% to 21,813 shares. | SEC filing Filed Jul 13, 2026 |
| Jul 9, 2026 | Planned (10b5-1) | Neil Gregory Almstead (Chief Technical Ops Officer) sold 2,464 shares at about $90.25 ($222K), marked as a 10b5-1 plan trade. Holdings down 4% to 60,299 shares. | SEC filing Filed Jul 13, 2026 |
| Jul 6, 2026 | Planned (10b5-1) | Mark Elliott Boulding (Exec. VP and CLO) sold 5,079 shares at about $85.08 ($432K), marked as a 10b5-1 plan trade. Holdings down 5% to 105,272 shares. | SEC filing Filed Jul 8, 2026 |
| Jul 6–7, 2026 | Planned (10b5-1) | Neil Gregory Almstead (Chief Technical Ops Officer) sold 46,774 shares between Jul 6 and Jul 7 at about $87.52 ($4.1M), marked as a 10b5-1 plan trade. Holdings down 44% to 60,299 shares. | SEC filing Filed Jul 8, 2026 |
| Jun 26, 2026 | Planned (10b5-1) | Neil Gregory Almstead (Chief Technical Ops Officer) sold 8,130 shares at about $85.26 ($693K), marked as a 10b5-1 plan trade. Holdings down 12% to 60,137 shares. | SEC filing Filed Jun 30, 2026 |
| Jun 24–25, 2026 | Planned (10b5-1) | Neil Gregory Almstead (Chief Technical Ops Officer) sold 26,283 shares between Jun 24 and Jun 25 at about $85.78 ($2.3M), marked as a 10b5-1 plan trade. Holdings down 30% to 60,137 shares. | SEC filing Filed Jun 26, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | Neil Gregory Almstead (Chief Technical Ops Officer) sold 23,749 shares at about $80.90 ($1.9M), marked as a 10b5-1 plan trade. Holdings down 28% to 60,137 shares. | SEC filing Filed Jun 24, 2026 |
| Jun 17, 2026 | Planned (10b5-1) | Christine Marie Utter (SVP, Chief Accounting Officer) sold 19,686 shares at $75.56 ($1.5M), marked as a 10b5-1 plan trade. Holdings down 22% to 70,199 shares. | SEC filing Filed Jun 22, 2026 |
| Jun 17, 2026 | Planned (10b5-1) | Mark Elliott Boulding (Exec. VP and CLO) sold 10,462 shares at about $78.65 ($823K), marked as a 10b5-1 plan trade. Holdings down 9% to 105,272 shares. | SEC filing Filed Jun 22, 2026 |
| Jun 10, 2026 | Planned (10b5-1) | Eric Pauwels (Chief Business Officer) sold 21,277 shares at $75.00 ($1.6M), marked as a 10b5-1 plan trade. Holdings down 22% to 73,411 shares. | SEC filing Filed Jun 12, 2026 |
| May 15, 2026 | Planned (10b5-1) | Mark Elliott Boulding (Exec. VP and CLO) sold 2,812 shares at about $72.18 ($203K), marked as a 10b5-1 plan trade. Holdings down 3% to 105,212 shares. | SEC filing Filed May 19, 2026 |
| May 14, 2026 | Planned (10b5-1) | Matthew B. Klein (CEO and Director) sold 12,572 shares at about $72.95 ($917K), marked as a 10b5-1 plan trade. Holdings down 3% to 393,998 shares. | SEC filing Filed May 15, 2026 |
| May 8, 2026 | Planned (10b5-1) | Mark Elliott Boulding (Exec. VP and CLO) sold 3,540 shares at about $78.97 ($280K), marked as a 10b5-1 plan trade. Holdings down 3% to 105,212 shares. | SEC filing Filed May 12, 2026 |
| Apr 21, 2026 | Planned (10b5-1) | Matthew B. Klein (CEO and Director) sold 2,850 shares at $70.91 ($202K), marked as a 10b5-1 plan trade. Holdings down 1% to 394,070 shares. | SEC filing Filed Apr 23, 2026 |
| Apr 6, 2026 | Planned (10b5-1) | Mark Elliott Boulding (Exec. VP and CLO) sold 2,265 shares at about $69.45 ($157K), marked as a 10b5-1 plan trade. Holdings down 2% to 105,212 shares. | SEC filing Filed Apr 8, 2026 |
| Apr 2, 2026 | Planned (10b5-1) | Lee Scott Golden (EVP & Chief Medical Officer) sold 829 shares at $67.99 ($56K), marked as a 10b5-1 plan trade. Holdings down 1% to 79,115 shares. | SEC filing Filed Apr 6, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Neil Gregory Almstead (Chief Technical Ops Officer) sold 52,003 shares at about $69.04 ($3.6M), marked as a 10b5-1 plan trade. Holdings down 46% to 60,137 shares. | SEC filing Filed Apr 3, 2026 |
| Mar 12, 2026 | Planned (10b5-1) | Matthew B. Klein (CEO and Director) sold 2,662 shares at $64.08 ($171K), marked as a 10b5-1 plan trade. Holdings down 1% to 396,920 shares. | SEC filing Filed Mar 13, 2026 |
| Mar 10, 2026 | Planned (10b5-1) | Stephanie Okey (Director) sold 15,167 shares at $70.00 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 65% to 8,000 shares. | SEC filing Filed Mar 12, 2026 |
| Mar 5, 2026 | Planned (10b5-1) | Stephanie Okey (Director) sold 6,333 shares at $63.38 ($401K), marked as a 10b5-1 plan trade. Holdings down 44% to 8,000 shares. | SEC filing Filed Mar 9, 2026 |
| Mar 5, 2026 | Planned (10b5-1) | Lee Scott Golden (EVP & Chief Medical Officer) sold 10,000 shares at $63.38 ($634K), marked as a 10b5-1 plan trade. Holdings down 11% to 79,944 shares. | SEC filing Filed Mar 9, 2026 |
| Mar 5, 2026 | Planned (10b5-1) | Neil Gregory Almstead (Chief Technical Ops Officer) sold 3,989 shares indirectly (by spouse) at $63.38 ($253K), marked as a 10b5-1 plan trade. Holdings by spouse down 59% to 2,737 shares. | SEC filing Filed Mar 9, 2026 |
| Feb 19, 2026 | Planned (10b5-1) | Mark Elliott Boulding (Exec. VP and CLO) sold 3,019 shares at about $69.48 ($210K), marked as a 10b5-1 plan trade. Holdings down 3% to 105,212 shares. | SEC filing Filed Feb 23, 2026 |
| Feb 18, 2026 | Planned (10b5-1) | Pierre Gravier (CFO) sold 2,992 shares at $69.36 ($208K), marked as a 10b5-1 plan trade. Holdings down 3% to 87,318 shares. | SEC filing Filed Feb 20, 2026 |
| Feb 18, 2026 | Planned (10b5-1) | Matthew B. Klein (CEO and Director) sold 7,371 shares at $69.36 ($511K), marked as a 10b5-1 plan trade. Holdings down 2% to 387,082 shares. | SEC filing Filed Feb 20, 2026 |
| Feb 18, 2026 | Planned (10b5-1) | Christine Marie Utter (SVP, Chief Accounting Officer) sold 2,494 shares at $69.36 ($173K), marked as a 10b5-1 plan trade. Holdings down 3% to 70,199 shares. | SEC filing Filed Feb 20, 2026 |
| Feb 18, 2026 | Planned (10b5-1) | Lee Scott Golden (EVP & Chief Medical Officer) sold 2,484 shares at $69.36 ($172K), marked as a 10b5-1 plan trade. Holdings down 3% to 89,944 shares. | SEC filing Filed Feb 20, 2026 |
| Feb 18, 2026 | Planned (10b5-1) | Neil Gregory Almstead (Chief Technical Ops Officer) sold 3,121 shares directly and indirectly (by spouse) at $69.36 ($216K), marked as a 10b5-1 plan trade. Direct holdings down 3% to 112,140 shares. | SEC filing Filed Feb 20, 2026 |
| Feb 18, 2026 | Planned (10b5-1) | Eric Pauwels (Chief Business Officer) sold 3,019 shares at $69.36 ($209K), marked as a 10b5-1 plan trade. Holdings down 4% to 77,122 shares. | SEC filing Filed Feb 20, 2026 |
| Feb 17–18, 2026 | Planned (10b5-1) | Mark Elliott Boulding (Exec. VP and CLO) sold 5,894 shares between Feb 17 and Feb 18 at about $69.33 ($409K), marked as a 10b5-1 plan trade. Holdings down 5% to 108,231 shares. | SEC filing Filed Feb 19, 2026 |
| Jan 8, 2026 | Planned (10b5-1) | Matthew B. Klein (CEO and Director) sold 2,514 shares at $76.45 ($192K), marked as a 10b5-1 plan trade. Holdings down 1% to 394,453 shares. | SEC filing Filed Jan 12, 2026 |
| Jan 8, 2026 | Planned (10b5-1) | Christine Marie Utter (SVP, Chief Accounting Officer) sold 1,034 shares at $76.45 ($79K), marked as a 10b5-1 plan trade. Holdings down 1% to 72,693 shares. | SEC filing Filed Jan 12, 2026 |
| Jan 8, 2026 | Planned (10b5-1) | Lee Scott Golden (EVP & Chief Medical Officer) sold 866 shares at $76.45 ($66K), marked as a 10b5-1 plan trade. Holdings down 1% to 92,428 shares. | SEC filing Filed Jan 12, 2026 |
| Jan 8–9, 2026 | Planned (10b5-1) | Mark Elliott Boulding (Exec. VP and CLO) sold 6,347 shares between Jan 8 and Jan 9 at about $77.06 ($489K), marked as a 10b5-1 plan trade. Holdings down 5% to 111,312 shares. | SEC filing Filed Jan 12, 2026 |
| Jan 8, 2026 | Planned (10b5-1) | Neil Gregory Almstead (Chief Technical Ops Officer) sold 940 shares directly and indirectly (by spouse) at $76.45 ($72K), marked as a 10b5-1 plan trade. Direct holdings down 1% to 115,196 shares. | SEC filing Filed Jan 12, 2026 |
| Jan 8–12, 2026 | Planned (10b5-1) | Eric Pauwels (Chief Business Officer) sold 7,348 shares between Jan 8 and Jan 12 at about $77.02 ($566K), marked as a 10b5-1 plan trade. Holdings down 8% to 80,141 shares. | SEC filing Filed Jan 12, 2026 |
| Jan 6, 2026 | Planned (10b5-1) | Pierre Gravier (CFO) sold 2,139 shares at $76.95 ($165K), marked as a 10b5-1 plan trade. Holdings down 2% to 90,310 shares. | SEC filing Filed Jan 8, 2026 |
| Jan 6–7, 2026 | Planned (10b5-1) | Matthew B. Klein (CEO and Director) sold 8,165 shares between Jan 6 and Jan 7 at about $77.15 ($630K), marked as a 10b5-1 plan trade. Holdings down 2% to 396,967 shares. | SEC filing Filed Jan 8, 2026 |
| Jan 6–7, 2026 | Planned (10b5-1) | Christine Marie Utter (SVP, Chief Accounting Officer) sold 2,616 shares between Jan 6 and Jan 7 at about $77.19 ($202K), marked as a 10b5-1 plan trade. Holdings down 3% to 73,727 shares. | SEC filing Filed Jan 8, 2026 |
| Jan 6–7, 2026 | Planned (10b5-1) | Lee Scott Golden (EVP & Chief Medical Officer) sold 1,982 shares between Jan 6 and Jan 7 at about $77.12 ($153K), marked as a 10b5-1 plan trade. Holdings down 2% to 93,294 shares. | SEC filing Filed Jan 8, 2026 |
| Jan 6–7, 2026 | Planned (10b5-1) | Mark Elliott Boulding (Exec. VP and CLO) sold 6,618 shares between Jan 6 and Jan 7 at about $77.31 ($512K), marked as a 10b5-1 plan trade. Holdings down 5% to 117,659 shares. | SEC filing Filed Jan 8, 2026 |
| Jan 6–7, 2026 | Planned (10b5-1) | Neil Gregory Almstead (Chief Technical Ops Officer) sold 2,411 shares directly and indirectly (by spouse) between Jan 6 and Jan 7 at about $77.19 ($186K), marked as a 10b5-1 plan trade. Direct holdings down 2% to 116,077 shares. | SEC filing Filed Jan 8, 2026 |
| Jan 6–7, 2026 | Planned (10b5-1) | Eric Pauwels (Chief Business Officer) sold 3,141 shares between Jan 6 and Jan 7 at about $77.18 ($242K), marked as a 10b5-1 plan trade. Holdings down 3% to 87,489 shares. | SEC filing Filed Jan 8, 2026 |
| Jan 5, 2026 | Planned (10b5-1) | Emma Reeve (Director) sold 734 shares at $76.00 ($56K), marked as a 10b5-1 plan trade. Holdings down 6% to 10,666 shares. | SEC filing Filed Jan 6, 2026 |
| Jan 5, 2026 | Planned (10b5-1) | Mark Elliott Boulding (Exec. VP and CLO) sold 2,266 shares at about $75.55 ($171K), marked as a 10b5-1 plan trade. Holdings down 2% to 120,901 shares. | SEC filing Filed Jan 6, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Glenn Md Phd Steele Jr. (Director) sold 12,000 shares at $76.35 ($916K), marked as a 10b5-1 plan trade. Holdings down 39% to 18,500 shares. | SEC filing Filed Jan 6, 2026 |
| Dec 30, 2025 | Planned (10b5-1) | Matthew B. Klein (CEO and Director) sold 8,089 shares at $76.64 ($620K), marked as a 10b5-1 plan trade. Holdings down 2% to 341,875 shares. | SEC filing Filed Jan 2, 2026 |
| Dec 19, 2025 | Planned (10b5-1) | Eric Pauwels (Chief Business Officer) sold 20,508 shares at about $77.26 ($1.6M), marked as a 10b5-1 plan trade. Holdings down 23% to 70,373 shares. | SEC filing Filed Dec 23, 2025 |
| Dec 17–18, 2025 | Planned (10b5-1) | Eric Pauwels (Chief Business Officer) sold 43,492 shares between Dec 17, 2025 and Dec 18, 2025 at about $75.40 ($3.3M), marked as a 10b5-1 plan trade. Holdings down 38% to 70,373 shares. | SEC filing Filed Dec 19, 2025 |
| Dec 3, 2025 | Planned (10b5-1) | Emma Reeve (Director) sold 733 shares at $78.62 ($58K), marked as a 10b5-1 plan trade. Holdings down 10% to 6,666 shares. | SEC filing Filed Dec 5, 2025 |
| Dec 2, 2025 | Planned (10b5-1) | Matthew B. Klein (CEO and Director) sold 3,428 shares at $79.07 ($271K), marked as a 10b5-1 plan trade. Holdings down 1% to 349,964 shares. | SEC filing Filed Dec 3, 2025 |
| Nov 25, 2025 | Planned (10b5-1) | Neil Gregory Almstead (Chief Technical Ops Officer) sold 71,928 shares at about $83.44 ($6.0M), marked as a 10b5-1 plan trade. Holdings down 42% to 100,625 shares. | SEC filing Filed Nov 26, 2025 |
| Nov 24–25, 2025 | Planned (10b5-1) | Allan Steven Jacobson (Director) sold 26,000 shares between Nov 24, 2025 and Nov 25, 2025 at about $82.00 ($2.1M), marked as a 10b5-1 plan trade. Holdings down 60% to 17,451 shares. | SEC filing Filed Nov 26, 2025 |
| Nov 24, 2025 | Planned (10b5-1) | Neil Gregory Almstead (Chief Technical Ops Officer) sold 35,572 shares at about $80.18 ($2.9M), marked as a 10b5-1 plan trade. Holdings down 26% to 100,625 shares. | SEC filing Filed Nov 26, 2025 |
| Nov 21, 2025 | Planned (10b5-1) | Emma Reeve (Director) sold 10,000 shares at $79.50 ($795K), marked as a 10b5-1 plan trade. Holdings down 60% to 6,666 shares. | SEC filing Filed Nov 25, 2025 |
| Nov 17, 2025 | Planned (10b5-1) | Mark Elliott Boulding (Exec. VP and CLO) sold 2,812 shares at about $75.99 ($214K), marked as a 10b5-1 plan trade. Holdings down 3% to 103,901 shares. | SEC filing Filed Nov 19, 2025 |
| Nov 12, 2025 | Planned (10b5-1) | Emma Reeve (Director) sold 7,333 shares at $74.50 ($546K), marked as a 10b5-1 plan trade. Holdings down 52% to 6,666 shares. | SEC filing Filed Nov 14, 2025 |
52 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 3, 2026, 9:00 AM ET 8-K | Reg FD disclosure (Item 7.01) Other event (Item 8.01) | SEC filing | |
| Oct 29, 2026, 4:10 PM ET 8-K | Earnings released (Item 2.02) Reg FD disclosure (Item 7.01) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow PTCT in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.